Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

ConclusionsIn patients with severe psoriatic arthritis, 24  weeks of treatment with ixekizumab resulted in improvements in both joint and skin symptoms. The safety profile in the severe population was consistent with the established safety profile of ixekizumab.Trial RegistrationClinicalTrials.gov identifier, NCT01695239.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research